Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 8, 2022 — Insmed Incorporated (Nasdaq:INSM), a
insmed
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 3, 2022 — Insmed Incorporated (Nasdaq: INSM),
Insmed Names Drayton Wise Chief Commercial Officer
BRIDGEWATER, N.J., May 23, 2022 — Insmed Incorporated (Nasdaq: INSM),
Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., May 6, 2022 — Insmed Incorporated (Nasdaq:INSM), a
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
–ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year
Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
BRIDGEWATER, N.J., April 21, 2022 — Insmed Incorporated (Nasdaq:INSM), a
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., April 7, 2022 — Insmed Incorporated (Nasdaq: INSM), a
Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
–Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., March 4, 2022 — Insmed Incorporated (Nasdaq: INSM),